SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
2019 · Journal of Thoracic Oncology · 86 citations
https://doi.org/10.1016/j.jtho.2019.05.029